Compare Torrent Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs FULFORD INDIA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA FULFORD INDIA TORRENT PHARMA/
FULFORD INDIA
 
P/E (TTM) x 37.1 398.8 9.3% View Chart
P/BV x 9.4 6.2 151.0% View Chart
Dividend Yield % 0.6 0.1 766.5%  

Financials

 TORRENT PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
FULFORD INDIA
Mar-14
TORRENT PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,964942 208.5%   
Low Rs1,245450 276.7%   
Sales per share (Unadj.) Rs453.4691.4 65.6%  
Earnings per share (Unadj.) Rs25.811.5 225.0%  
Cash flow per share (Unadj.) Rs62.315.4 405.5%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.10.3 368.7%  
Book value per share (Unadj.) Rs279.2380.0 73.5%  
Shares outstanding (eoy) m169.223.90 4,339.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.51.0 351.5%   
Avg P/E ratio x62.260.7 102.5%  
P/CF ratio (eoy) x25.845.3 56.8%  
Price / Book Value ratio x5.71.8 313.8%  
Dividend payout %65.917.4 377.8%   
Avg Mkt Cap Rs m271,5132,714 10,002.7%   
No. of employees `00013.60.4 3,062.6%   
Total wages/salary Rs m14,038505 2,779.8%   
Avg. sales/employee Rs Th5,642.66,073.0 92.9%   
Avg. wages/employee Rs Th1,032.41,137.4 90.8%   
Avg. net profit/employee Rs Th320.9100.7 318.7%   
INCOME DATA
Net Sales Rs m76,7282,696 2,845.6%  
Other income Rs m571125 454.9%   
Total revenues Rs m77,2992,822 2,739.3%   
Gross profit Rs m19,831-46 -42,738.4%  
Depreciation Rs m6,17715 40,637.5%   
Interest Rs m5,03810 53,026.3%   
Profit before tax Rs m9,18754 16,918.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,25410 13,057.3%   
Profit after tax Rs m4,36345 9,760.9%  
Gross profit margin %25.8-1.7 -1,501.9%  
Effective tax rate %13.617.7 77.2%   
Net profit margin %5.71.7 343.0%  
BALANCE SHEET DATA
Current assets Rs m50,3751,738 2,898.0%   
Current liabilities Rs m51,653545 9,482.9%   
Net working cap to sales %-1.744.3 -3.8%  
Current ratio x1.03.2 30.6%  
Inventory Days Days9248 190.0%  
Debtors Days Days684 1,586.6%  
Net fixed assets Rs m83,64812 702,926.9%   
Share capital Rs m84639 2,169.7%   
"Free" reserves Rs m46,3971,443 3,215.3%   
Net worth Rs m47,2441,482 3,187.8%   
Long term debt Rs m39,1290-   
Total assets Rs m141,2092,077 6,799.7%  
Interest coverage x2.86.7 42.0%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.51.3 41.8%   
Return on assets %6.72.6 255.1%  
Return on equity %9.23.0 306.2%  
Return on capital %12.34.3 286.5%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m22,10317 128,503.5%   
Fx outflow Rs m5,522673 820.2%   
Net fx Rs m16,581-656 -2,527.8%   
CASH FLOW
From Operations Rs m17,98190 19,978.7%  
From Investments Rs m-2,413105 -2,306.7%  
From Financial Activity Rs m-13,145-14 93,223.4%  
Net Cashflow Rs m2,380181 1,318.7%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 3.8 184.7%  
FIIs % 12.6 0.1 12,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 21.2 41.5%  
Shareholders   26,511 4,783 554.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  BIOCON   IPCA LABS  NATCO PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Apr 16, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS